Mevir (Brivudine)

Brivudine is taken orally and converted inside cells to its active triphosphate form. This metabolite competitively inhibits the viral DNA polymerase enzyme, blocking the synthesis of viral DNA and preventing the varicella‑zoster virus from multiplying.

The specific dosage of Mevir is determined by the prescribing clinician based on the patient’s age, weight, renal function, and severity of infection. Healthcare professionals follow local prescribing guidelines to set the appropriate regimen.

Data on brivudine use in pregnancy and lactation are limited. Generally, the drug is avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Mevir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mevir (brivudine) is a nucleoside analogue that offers once‑daily dosing and rapid viral suppression, whereas acyclovir and valacyclovir are guanosine analogues typically taken multiple times daily. Clinical studies suggest brivudine may provide faster lesion healing, but choice depends on patient factors, drug availability, and physician preference.

Store Mevir tablets at temperatures below 25 °C, in the original container, and protect them from moisture and direct sunlight. Keep the medication out of reach of children and do not use it after the expiry date printed on the packaging.

Mevir is taken orally with a glass of water, preferably on an empty stomach to improve absorption. Patients should follow the dosing schedule prescribed by their clinician and complete the full course, even if symptoms improve early.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction indicated by elevated liver enzymes, and hematologic abnormalities like neutropenia or thrombocytopenia. If any of these occur, the medication should be stopped immediately and medical attention sought.

Mevir is contraindicated in individuals with known hypersensitivity to brivudine or any tablet excipients, in patients with severe renal impairment, and in those receiving fluoropyrimidine chemotherapy (e.g., 5‑fluorouracil or capecitabine) because of the risk of life‑threatening toxicity.